Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) -- (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium () Congress 2026 taking place from January 8 to 10, 2026 in San Franc...
Perspective Therapeutics to Participate in Upcoming December Conferences SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday, December 2, 2025Time: 1:00 - 1:25 p....
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results Updated interim results from the Company’s [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy’s compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple meetingsEnrolled eight patients into Cohort 3 (6.0 mCi) of the [212Pb]VMT-α-NET study within three months of opening the cohortVisibility on updates for all three of the Company’s clinical-stage potential new medicines expected throughout 2026 based on strong recruitment of patients and clin...
Perspective Therapeutics to Participate in Upcoming November Conferences SEATTLE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Truist Securities BioPharma Symposium – 1x1 onlyDate: Thursday, November 6, 2025Location: New York, NY UBS Global Healthcare Conference – Fi...
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results SEATTLE, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 10, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at . About Perspective Therapeutics, ...
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025 Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on studyInitial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026Pe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.